CEFSULODIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H20N4O8S2
Molecular Weight	532.546
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=CC=[N+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](C4=CC=CC=C4)S(O)(=O)=O)C3=O)C([O-])=O)C=C1

InChI

InChIKey=SYLKGLMBLAAGSC-QLVMHMETSA-N

InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html

Cefsulodin is a third-generation of cephalosporin antibiotic with a narrow spectrum of activity. It has a specific activity against Pseudomonas aeruginosa. Cefsulodin’s targets are bacterial penicillin binding proteins. Drug is indicated for the treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2112536 \| https://www.ncbi.nlm.nih.gov/pubmed/3545069 \| https://www.ncbi.nlm.nih.gov/pubmed/3898066	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Lower respiratory tract infections 52 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Urinary tract infections 207 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Skin and soft tissue infections 33 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Gynecological infections 8 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Bone and joint infections 28 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Intra-abdominal infections 50 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
CNS infections 2 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Sepsis 74 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8583	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.

PubMed

Title	Date	PubMed
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity.	1992	1384868
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera.	1981-01	6166604

Patents

Sample Use Guides

In Vivo Use Guide

Intramuscular: 0.5-1 g daily in 2-4 divided doses Intravenous: 0.5-1 g. in severe cases up to 2 g.

Route of Administration: Other

In Vitro Use Guide

Cefsulodin was an effective bactericidal agent against P. aeruguiosa and S. aureus. An apparent decrease in the number of living bacteria was observed at a concentration of 6.25 ug/ml for P. aerugnosa U 31 and 3.13 ug/ml for S. aureus FDA 209- P.

Name

Type

Language

J01DD03

Preferred Name

English

CEFSULODIN

Official Name

English

CEFSULODIN [MI]

Common Name

English

cefsulodin [INN]

Common Name

English

4-CARBAMOYL-1-(((6R,7R)-2-CARBOXY-8-OXO-7-((2R)-2-PHENYL-2-SULFOACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYLPYRIDINIUM HYDROXIDE, INNER SALT

Common Name

English

CEFSULODIN [JAN]

Common Name

English

Cefsulodin [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

J01DD03